论文部分内容阅读
目的在对宫颈癌和癌前病变的临床诊断和筛查实践中,通过回顾性分析比较TCT细胞学及高危HPV基因分型检测的优势,评判其临床应用价值。方法研究了2015年1月至2015年12月期间,在日照市人民医院就诊、有宫颈病变并进行了HR-HPV-DNA、TCT检测的患者共765例,对有1项以上异常并且知情同意的246例患者进行病理组织学检查,其中161例患者检查结果为阳性,并以此为阳性判断标准,比较两种方法学单用与联合应用对宫颈癌和癌前病变检出的灵敏度、特异性、准确度。结果 HR-HPV-DNA检测对宫颈癌和癌前病变筛查灵敏度最高,特异性、准确度低于TCT检测,两者联合检测特异性、准确度高于单独采用TCT细胞学检查或HR-HPV-DNA检测,其中联合检测特异性与单独采用HR-HPV-DNA检测相比差异具有统计学意义(P<0.05)。结论宫颈组织的细胞学和HR-HPV-DNA分型检测是宫颈癌筛查有效的方法,联合采用两种方法检测,更有利于宫颈癌的早期诊断。
Objective To evaluate the clinical value of TCT cytology and high-risk HPV genotyping by retrospectively analyzing the clinical diagnosis and screening of cervical cancer and precancerous lesions. Methods From January 2015 to December 2015, a total of 765 patients with cervical lesions and HR-HPV-DNA and TCT were enrolled in Rizhao People’s Hospital. Among them, there were 765 patients with more than one abnormality and informed consent Of 246 patients with histopathological examination, of which 161 patients with positive test results, and as a positive diagnostic criteria, compared with the two methods of single and combined use of cervical cancer and precancerous lesions detected sensitivity, specificity Sexuality, accuracy. Results The HR-HPV-DNA test showed the highest sensitivity, specificity and accuracy for detecting cervical cancer and precancerous lesions compared with TCT test. The specificity of HR-HPV-DNA test was higher than TCT cytology or HR-HPV alone -DNA. The specificity of combined detection was significantly higher than HR-HPV-DNA alone (P <0.05). Conclusion Cervical cytology and HR-HPV-DNA typing is an effective method for cervical cancer screening. Combined with two methods, it is more conducive to the early diagnosis of cervical cancer.